Antismoking groups sued the US government over the long-awaited menthol cigarette ban; the fill rate for Adderall and Vyvanse dropped more than 10% in 2 years despite soaring demand; the Biden administration has responded to offers from the manufacturers of drugs selected for Medicare pricing negotiations.
Antismoking groups sued the US government on Tuesday over the long-awaited menthol cigarette ban, which the Biden administration has been delaying for months, according to the Associated Press. This lawsuit is the latest effort to force the government to ban menthol cigarettes, which are disproportionately used by young people and Black smokers; advocates are concerned that the federal plan could be derailed by election-year politics. Late last year, White House officials said they would take until March to review the rule. After the March deadline passed, 3 nonprofit groups, including Action on Smoking and Health, filed their lawsuit in a California federal court. A lawyer who helped file the lawsuit said the government will have about 2 months to respond.
A recent analysis found that the fill rate for Adderall and Vyvanse, 2 commonly prescribed drugs for attention-deficit/hyperactivity disorder (ADHD), dropped more than 10% in 2 years despite soaring demand, according to Axios. The ADHD drug shortage has occurred for nearly 18 months with no clear end in sight and is among many generic medicine shortages in recent years. Likely drivers of the shortages include drug production caps and pandemic-driven demand increases. The problem has recently been getting attention on Capitol Hill and from federal regulators. On Tuesday, HHS said in a white paper that statutory changes and more funding are needed for “more impactful and enduring solutions” than the ones it has already taken to address the shortages.
The Biden administration announced Tuesday that it has responded to offers from the manufacturers of 10 high-cost drugs selected for the Medicare drug pricing negotiations but provided no further details, according to Reuters. CMS picked the first 10 drugs for negotiation in August and sent its initial price offers in February. The companies had until March 1 to respond, and all did so. Each company can meet with CMS up to 3 times for further negotiations before a final price is announced on August 1. However, the negotiated prices will not come into effect until 2026. The drugs selected for negotiation are manufactured by Bristol Myers Squibb, Johnson & Johnson, Eli Lilly, Novo Nordisk, Pfizer, Merck & Co, AbbVie, Amgen, and Boehringer Ingelheim.
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Covering antiobesity medications like semaglutide could save Medicare around $500 million annually; preliminary CDC data showed a 3% decline in the number of US overdose deaths last year; the Biden administration recently announced the first national maternal mental health strategy.
Read More